// App-Quantinova.ai

P513 : CPX-351 TREATMENT FOR ACUTE MYELOID LEUKEMIA IN ENGLAND: REAL-WORLD OUTCOMES IN ADULTS AGED <60 YEARS VERSUS ≥60 YEARS

Researchers

Presenter

  • Alex Legg

Principal Investigators

  • Ruvimbo Muzwidzwa

  • Alexandrina Lambova

  • Katherine Styles

  • Pesheya Doubleday

  • Greg Medalla

Medical Centers

  • IQVIA Inc.,London,Royaume-uni

  • Jazz Pharmaceuticals,Oxford,Reino Unido

  • Jazz Pharmaceuticals,Oxford,Vereinigtes Königreich

  • IQVIA Inc.,London,Regno Unito

  • Jazz Pharmaceuticals,Oxford,Storbritannien

  • IQVIA Inc.,London,Vereinigtes Königreich

  • Jazz Pharmaceuticals,Oxford,Соединённое Королевство

  • IQVIA Inc.,London,Regno Unito

  • IQVIA Inc.,London,Соединённое Королевство

  • Jazz Pharmaceuticals,Oxford,United Kingdom

  • Jazz Pharmaceuticals,Oxford,Verenigd Koninkrijk

  • IQVIA Inc.,London,Verenigd Koninkrijk

  • NCRI, London, United Kingdom

  • Jazz Pharmaceuticals,Oxford,Reino Unido

  • IQVIA Inc.,London,Storbritannien

  • Jazz Pharmaceuticals,Oxford,Royaume-uni

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

  • Chronic myelomonocytic leukemia

Biomarkers

  • Hematocrit

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • daunorubicin + cytarabine

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved